NanoCell
Intrauterine Treatment for Improving Embryo Implantation Rates
Company Overview
Snapshot
Founded in January 2015 by Prof. Irit Sagi, NanoCell operates with 1–10 employees. The company secured its Pre-Seed funding round in December 2023, with Arieli Group participating. NanoCell holds one patent for its biopharmaceutical technologies.
Business overview
NanoCell is a Health Tech & Life Sciences company focused on advancing women's reproductive health through biopharmaceutical technologies. The company develops a proprietary intrauterine treatment designed to significantly improve embryo implantation rates in both humans and livestock. Its core technology involves using enzymatically remodeled extra-cellular matrix (ECM) to enhance the efficiency of embryo implantation, operating within the Medical Devices and Pharma & Medical Biotechnology sectors.
Company Intelligence Q&A
- What is NanoCell's primary focus?
- NanoCell is dedicated to advancing women's reproductive health through biopharmaceutical technologies, specifically focusing on improving embryo implantation rates.
- Who founded NanoCell?
- NanoCell was founded by Prof. Irit Sagi in January 2015.
- What is NanoCell's core technology?
- NanoCell is developing a method, kit, and composition that uses enzymatically remodeled extra-cellular matrix (ECM) to increase the implantation rate of embryos in both humans and livestock.
- When did NanoCell cease operations?
- NanoCell ceased to operate in August 2024.
- Which investor participated in NanoCell's Pre-Seed funding round?
- In December 2023, Arieli Group participated in NanoCell's Pre-Seed funding round.